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ABSTRACT 
Thyroid hormone receptor (TR) activation affects numerous metabolic processes 
involved in lipid and glucose metabolism, with implications for diseases such as 
obesity, diabetes, and hyperlipidemia. Thyroid hormone and synthetic TR 
agonists are known to decrease serum lipids and induce fat loss. Here we 
investigate the effects of TR agonists on lipid homeostasis in the liver and 
adipose tissue. 
 
TR agonists lower serum cholesterol levels in rodents, monkeys, and humans. 
While it is clear that TR activation reduces serum cholesterol, the mechanism 
behind this effect is less apparent. Although TR agonists have been reported to 
affect several pathways involved in cholesterol metabolism, the most notable 
rationale has been that thyroid hormones stimulate expression of the LDL 
receptor (LDLR). Here we show TR activation can markedly reduce serum 
cholesterol in mice devoid of LDLR by inducing Cyp7a1 expression and 
stimulating the conversion and excretion of cholesterol as bile acids. Thus, TR 
agonists may represent a promising therapeutic to treat hypercholesterolemia 
disorders for which LDLR induction is not fully effective.  
 
Thyroid hormones have long been known to stimulate basal metabolic rate and 
elicit thermogenesis, effects generally attributed to the activation of brown 
adipose tissue (BAT). However, the relationship between TR activation and 
vi 
thermogenesis is complex and not fully resolved. Here we show that thyroid 
hormone and the TR agonist GC-1 induce a BAT-like program of adaptive 
thermogenesis and uncoupled respiration in subcutaneous white adipose tissue 
(WAT), which appears to directly mediate an increase in metabolism and marked 
fat loss. The TR mediated conversion of white to beige fat, an action 
accompanied by striking anti-diabetic and anti-obesity properties, may represent 
an unrecognized component of TR-mediated thermogenesis and demonstrates 
the profound pharmacological potential of beiging of WAT. 
 
In conclusion, we have shown that TR activation in the liver reduces serum 
cholesterol independent of the LDLR via the induction of hepatic Cyp7a1 and that 
TR activation in WAT elicits a functional conversion of white to brown fat. These 
data show the TR activation has beneficial effects on lipid homeostasis in the 
liver and adipose tissue and may suggest an important strategy to combat 
metabolic diseases. 
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CHAPTER 1 INTRODUCTION 
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THYROID HORMONE: MECHANISM OF ACTION 
Thyroid Hormone 
Thyroid hormone actions are pleiotropic, involving the regulation of many 
physiological systems. Their actions are important in development as well as in 
adulthood. Thyroid hormones regulate the growth and maturation of many organs 
during embryonic development. During adulthood, the major function of thyroid 
hormone is the regulation of metabolism and function of many tissues, such as 
the liver, heart, skin, muscle, and adipose tissue (1).  
 
Regulation of Thyroid Hormone Levels  
As an important metabolic regulator, thyroid hormone levels must be tightly 
regulated to avoid metabolic dysfunction. The thyroid gland synthesizes two 
forms of thyroid hormone; the pro-hormone thyroxine (T4) as well as a small 
amount of the active hormone triiodothyronine (T3). Thyroid-stimulating hormone 
(TSH) stimulates the production of thyroid hormone in the thyroid gland. In a 
negative feedback loop, thyroid hormone represses the production of TSH in the 
hypothalamus and pituitary gland, referred to as the hypothalamus-pituitary-
thyroid (HPT) axis (2).  
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Figure 1-1. Iodothyronine deiodinase. 
Thyroid hormones are activated and inactivated by specific chemical reactions involving 
iodothyronine deiodinases. 
 
Intracellular levels of thyroid hormone are regulated within the target tissues by 
thyroid hormone transporters and monodeiodination enzymes. While it was 
previously assumed that the lipophilic property of thyroid hormone allowed the 
molecule to enter cells through passive diffusion, this view has changed since the 
discovery of specific thyroid hormone transporters. These thyroid hormone 
transporters, such as MCT8 and OATP14 (3), add an additional mechanism to 
regulate thyroid hormone levels within the cells. Intracellular levels of T3 are fine 
tuned further by the action of type I and II deiodonases (Dio1 and Dio2) that 
convert T4 to T3 (Figure 1-1). Additionally, T4 and T3 can be inactivated by type I 
and III deiodonases (Dio1 and Dio3), which convert T4 to reverse T3 and T3 to T2 
(4).  
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Thyroid Hormone Receptors 
Thyroid hormone actions are initiated by interaction with the thyroid hormone 
receptors (TRs), which are members of the superfamily of nuclear receptors (5). 
TRs bind to specific DNA sequences (thyroid hormone response elements) to 
promote the regulation of specific target genes. Thyroid hormone binding leads to 
conformational changes in the receptors resulting in an exchange of 
corepressors for coactivators. 
 
 
Figure 1-2. Schematic of TR isoform α and β . 
The functional properties and length of TR α and β are indicated in above diagrams. 
 
Two major TR isoforms are encoded by two distinct genes designated TRα and 
TRβ (Figure 1-2), encoded on human chromosome 17 and 3, respectively (6). 
The two TRs are highly homologous with the ligand-bind domain and DNA-
binding domain being 86% and 82% identical, respectively. It is controversial 
whether the TRα and TRβ isoforms can compensate for each other but it 
appears that, depending upon context, TR isoforms can have both redundant 
roles and specific functions. The degree of redundancy seems to be largely 
5 
dependent upon the level of coexpression within a tissue. TRα is expressed 
ubiquitously in most tissues, with particularly high expression in the heart, while 
TRβ is expressed predominately in the liver and kidney (7).  
 
Mouse Models of Thyroid Hormone Action 
Several TR knockout and knockin mouse models have been generated to identify 
the specific actions of each TR isoform. While the first knockout mice did not 
show phenotypical abnormalities concerning adipose metabolism or alterations in 
energy balance (8–10), work with TR point mutations and dominant negative 
mutations identified phenotypes related to adipose tissue and energy balance 
(11–14). Overall, TRα seems to be required for proper thermogenesis, while TRβ 
regulates cholesterol metabolism. The TR double knockout mice as well as 
hypothyroid mice have decreased body temperature and basal metabolic rate 
(15, 16). These mice, which are devoid of all TRs, also show growth retardation 
and delayed skeletal maturation along with increase in adiposity. Furthermore, 
the TRα P398H mutant knockin has increased visceral adiposity, 
hyperleptinemia, a fourfold increase in body fat, increased basal glucose and 
insulin, and impaired lipolysis (17). Thus far, nearly all reports have utilized whole 
body knockouts and knockins of the TR isoforms. Therefore, it is difficult to 
discern tissue-specific effects of individual isoforms. 
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Thyroid Hormone Imbalances, Disease, and Therapy 
The connection between thyroid hormone and metabolism is exemplified by 
hyperthyroid and hypothyroid patients. Hyperthyroidism is a clinical disorder 
characterized by an excess production of thyroid hormone. Hyperthyroidism 
causes a hypermetabolic state characterized by increased energy expenditure 
and weight loss despite marked hyperphagia, tachycardia (increased heart rate) 
with possible atrial arrhythmias, muscle fatigue, anxiety, irritability, and 
preference for cold temperatures (18). On the other hand, hypothyroidism is 
when the thyroid gland does not produce enough thyroid hormone. Common 
symptoms of hypothyroidism are weight gain, high serum cholesterol, poor ability 
to tolerate cold and mood disturbances (18). Hypothyroidism is easily treated 
with thyroid hormone replacement therapy.  
 
Patients with resistance to thyroid hormone (RTH) have elevated T4 and T3 and 
non-suppressed TSH. Despite the elevated thyroid hormone levels, patients with 
RTH do not exhibit the usual symptoms and metabolic consequences of excess 
thyroid hormone. RTH is generally caused by a mutation in TRβ that impairs 
thyroid hormone action, although defects in thyroid hormone transport (19, 20) 
and metabolism (21) have recently been identified.  
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THYROID HORMONE RECEPTORS AND 
CHOLESTEROL HOMEOSTASIS 
Cholesterol Regulation 
TRs have a well established role in hepatic cholesterol metabolism and 
regulation of serum cholesterol levels. Cholesterol is the building block for cell 
membranes and essential for proper cell membrane permeability and fluidity. 
Cholesterol is also an important precursor molecule for many biochemical 
pathways such as vitamin D and steroid hormones. However, cholesterol in 
excess through a high-fat diet leads to the progression of atherosclerosis. 
Elevated levels of circulating low-density lipoprotein (LDL) cholesterol is 
associated with an increased risk of atherosclerotic cardiovascular disease (22). 
Conversely, decreased risk of cardiovascular disease is associated with the 
reductions in serum cholesterol levels that occur with the use of hepatic 3-
hydroxy-3-methyl-glutaryl coenzyme A reductase (HMGCR) inhibitors, commonly 
known as statins (22).  
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Figure 1-3. Schematic of cholesterol flux. 
LDL–cholesterol particles can deposit cholesterol in the artery wall to form plaques or can be 
reabsorbed into the liver through interactions with LDLR. For the HDL pathway, precursor 
particles containing apolipoprotein A1 (APOA1) are secreted into the circulation, where they pick 
up cholesterol from atherosclerotic plaques and other sources to become mature HDL particles. 
HDL particles are taken up by the liver through interactions with liver HDL receptors, scavenger 
receptor B1 (SR-B1). Liver cholesterol content is regulated by the rate of synthesis and the rate of 
conversion to bile acids, which are secreted into the intestine. The enzymes 3-hydroxy-3- methyl-
glutaryl-CoA reductase (HMGCR) and cytochrome P450 7A1 (CYP7A1) regulate important steps 
in cholesterol metabolism. 
 
Regulation of cholesterol homeostasis is complex and only parts of cholesterol 
regulation are understood, see Figure 1-3. Intracellular cholesterol levels are 
sensed by the sterol-regulatory element binding protein (SREBP) (23). When 
cholesterol levels are low, SREBP translocates into the nucleus, where it acts as 
a transcription factor and stimulates transcription of many genes including 
HMGCR and LDL receptor (LDLR). HMGCR is the rate-limiting enzyme in the 
synthesis of cholesterol. LDLR scavenges the blood for LDL-cholesterol and 
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takes up cholesterol into the cell. When cholesterol levels are high, HMGCR is 
degraded. 
 
Cholesterol from peripheral tissues is transported back to the liver via high-
density lipoprotein (HDL) through a process called reverse cholesterol transport 
(RCT). HDL-cholesterol protects against cardiovascular disease by removing 
cholesterol from atherosclerotic plaques, which is then taken up into the liver via 
the HDL scavenger receptor B1 (SR-B1). HDL-associated cholesterol can then 
be converted to bile acids by cholesterol 7α-hydroxylase (Cyp7a) and excreted.  
 
Effects of Thyroid Hormones on Cholesterol 
Hypothyroidism is associated with hypercholesterolemia in humans and animals 
due to a reduced clearance of serum LDL-cholesterol resulting from decreased 
LDLR (24–27). The cholesterol-lowering effects of thyroid hormone replacement 
therapy in hypothyroid patients have been previously described (28). Although 
thyroid hormone can lower serum cholesterol, the treatment of 
hypercholesterolemia by thyroid hormone is limited due to deleterious cardiac 
and other side effects (29). However, synthetic thyroid hormone analogues, 
which have receptor-subtype selective and liver-selective activities and are often 
referred to as thyromimetics, have been developed for cholesterol lowering (30–
33). Several thyromimetics have been shown to possess cholesterol-lowering 
actions in mice, monkeys and humans (30–33).  
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The activation of TR clearly causes a decrease in LDL cholesterol, however the 
mechanism(s) by which TR activation reduces serum cholesterol is not well 
understood. While TR agonism has been shown to affect multiple pathways 
involved in cholesterol homeostasis (34–36), the relative importance of individual 
factors in mediating serum cholesterol reduction is unclear. Increased LDLR 
expression is the principal mechanism by which many drugs (including statins) 
lower cholesterol (37), and the TRs have been shown previously to induce LDLR 
(34, 38, 39); it is perhaps not surprising that this action is the most often-
described mechanistic rationale for cholesterol reduction by the TRs (28). 
Additionally, thyroid hormone analogues also accelerate clearance of cholesterol 
by the liver by increasing SR-B1, increasing the activity of CYP7A1, and 
increasing fecal excretion of cholesterol as bile acids (38, 40, 41). 
 
THYROID HORMONES AND ENERGY 
HOMEOSTASIS 
The Role of Thyroid Hormones in Metabolic Regulation 
It is well known that thyroid hormones are involved in the regulation of 
thermogenesis, body temperature, and energy balance (42). In humans, 
hypothyroidism is associated with weight gain and hypersensitivity to cold while 
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in hyperthyroidism is patients experience weight loss and difficulty tolerating the 
heat (18).  
 
Generally, thyroid hormone-induced thermogenesis is attributed to BAT, 
however, a full understanding of the mechanisms by which thyroid hormone 
increases metabolic rate remains unclear (42). The role of thyroid hormone in 
BAT is evident in Dio2-/- mice, which are hypothermic due to impaired BAT 
thermogenesis, while the administration of T3 rescues the thermogenic defects 
(43). Thyroid hormones have been shown to increase uncoupling protein-1 
(UCP1) expression, mitochondrial number, oxidative phosphorylation rates and 
thermogenesis in BAT (44, 45). Additionally, thyroid hormone upregulates genes 
involved in mitochondrial respiration (46). 
 
In addition to BAT-mediated thermogenesis, it is generally accepted that other 
tissues also contribute to thyroid hormone-induced thermogenesis. Thyroid 
hormone has been shown to induce sarcoplasmic reticulum calcium ATPase 
(SERCA) in muscle, which induces Ca2+ cycling and increase energy expenditure 
leading to heat production (47, 48). Additionally, thyroid hormone induces futile 
cycles in glucose and fat metabolism, in which substrates and products are 
interconverted, leading to heat production (49–51). Thus, although thyroid 
hormone plays a clear role in thermogenesis and metabolic regulation, it is not 
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fully apparent how much each of these actions contributes to the effects of 
thyroid hormone on systemic metabolism.  
 
Adipose Tissue Types and Function 
Thyroid hormone increases systemic metabolism and energy demand, which 
affects adipose tissue biology. Adipose tissue is specialized in the transport, 
synthesis, and storage of lipids. Although excess caloric intake and decreased 
energy expenditure promote overall weight gain, visceral adiposity is particularly 
associated with cardiometabolic risk (52). There are two types of adipose tissue: 
white adipose tissue (WAT) and brown adipose tissue (BAT). While WAT 
functions to store energy in the form on triglycerides and comprises a reservoir of 
energy to be use in times of caloric demand, BAT can dispose of excess energy 
by converting it to heat (53–55). 
 
WAT is morphologically characterized by a single large lipid droplet, which fills 
the intracellular space. There are two types of WAT, subcutaneous and visceral 
fat. While these types are based on anatomical location, there are differences in 
lipolytic sensitivity, insulin sensitivity, and inflammatory tendency. Increase in 
visceral fat is associated with elevated risk of metabolic dysfunction such as 
insulin resistance, type 2 diabetes and cardiovascular disease (52, 56–60). While 
subcutaneous fat is associated with improvement of insulin sensitivity, and 
lowered risk of type 2 diabetes and atherosclerosis (61–65). However the 
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molecular mechanism for these differences between the WAT depots is still 
unclear.  
 
BAT is specialized in non-shivering adaptive thermogenesis and functions to 
generate heat in exchange for calories. BAT is morphologically characterized by 
multilocular lipid droplets and abundant mitochondria. The dissipation of heat is 
generated by UCP1, which uncouples oxidative phosphorylation, thereby 
dissipating the proton gradient and leading to the generation of heat instead of 
ATP. Its exceptional ability to burn excess calories as heat is considered anti-
obesogenic (66, 67). While BAT was thought to be found only in hibernating 
animals, small rodents, and newborns, recent studies have shown that BAT 
exists in humans and is associated with leanness (68–72). This has renewed 
interest in the pharmacological potential of the anti-obesogenic actions of BAT. 
 
Recent studies have shown the ability to impart BAT-like function within WAT of 
rodents and humans (73–76). These brown-like cells that arise within WAT 
depots have come to be called recruitable brown fat cells, brown-in-white (brite) 
cells, and beige cells. This process of browning of WAT is enhanced by cold 
adaptation or β-adrenergic stimulation (77–82). The brown-like transformation of 
WAT is most predominant in the subcutaneous depot, whereas visceral fat is less 
susceptible to browning (77, 79, 83, 84). The mechanism by which beige cells 
emerge is not yet clear, although a recent lineage-tracing study suggested that 
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beige adipocytes arise from distinct progenitor cells residing in WAT depots (85) 
(Figure 1-4). Regardless of mechanism, the ability to functionally convert white 
into brown-like adipocytes appears to hold promise as a method to combat 
obesity and diabetes.  
 
 
Figure 1-4. Brown and beige fat differentiation. 
(A) Brown adipocytes are derived from a Myf5-expressing progenitor population. Thermogenesis 
in mature brown adipocytes is activated by norepinephrine (NE), a β3 agonist, released from 
sympathetic neurons. NE signals through β-adrenergic receptors to increase the expression and 
activity of Pgc-1α, a transcriptional coactivator that coordinates gene programming in response to 
activation. (B) In inguinal fat, β-adrenergic stimulation triggers predominantly de novo 
differentiation of precursor cells (large arrow). There are also possibilities that under some 
conditions mature white fat cells can transdifferentiate into beige cells (small dashed arrow). 
 
Thyroid Hormones in Adipose Tissues  
As a key modulator of energy balance and thermogenesis, excess thyroid 
hormone elicits substantial changes in lipid metabolism (32, 42). Thyroid 
hormone modulates the development and metabolism of adipose tissue in both 
15 
physiological and pathological conditions. All TR isoforms are expressed in WAT 
and BAT, with TRα being the predominant isoform. Studies have shown thyroid 
hormones play essential role in BAT physiology and are necessary for full 
thermogenic response. Thyroid hormones also induce lipolysis in WAT, which is 
generally thought to be indirect and due to an increase in systemic metabolic rate 
and energy demand. However, a recent study has suggested a direct effect of 
thyroid hormones in WAT metabolism due to the induction of Ucp1 expression 
(45). Regardless of mechanism, TR activation clearly elicits fat loss. Thus, 
thyroid hormone analogues have long been pursued as anti-obesity agents. 
These compounds have been shown to induce fat loss and elevate metabolic 
rate in mice and rats (32), suggesting that the TR agonists could hold potential as 
anti-obesity therapeutics. 
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CHAPTER 2 THYROID HORMONE RECEPTOR 
AGONISTS REDUCE SERUM CHOLESTEROL 
INDEPENDENT OF THE LDL RECEPTOR 
17 
The majority of cholesterol reduction therapies, such as the statin drugs, work 
primarily by inducing the expression of hepatic LDLRs, rendering these 
therapeutics only partially effective in animals lacking LDLRs. While thyroid 
hormones and their synthetic derivatives, often referred to as thyromimetics, 
have been clearly shown to reduce serum cholesterol levels, this action has 
generally been attributed to their ability to increase expression of hepatic LDLRs. 
Here we show for the first time that the thyroid hormone T3 and the TRβ selective 
agonists GC-1 and KB2115 are capable of markedly reducing serum cholesterol 
in mice devoid of functional LDLRs by inducing Cyp7a1 expression and 
stimulating the conversion and excretion of cholesterol as bile acids. Based on 
this LDLR-independent mechanism, thyromimetics such as GC-1 and KB2115 
may represent promising cholesterol lowering therapeutics for the treatment of 
diseases such as homozygous familial hypercholesterolemia, a rare genetic 
disorder caused by a complete lack of functional LDLRs, for which there are 
limited treatment options as most therapeutics are only minimally effective. 
 
INTRODUCTION 
Familial Hypercholesterolemia (FH) is a genetic disorder characterized by 
elevated levels of serum cholesterol and associated with early onset 
cardiovascular disease. FH is a manifestation of a misfunctional allele encoding 
the low density lipoprotein receptor (LDLR), the primary receptor responsible for 
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clearing cholesterol laden low-density lipoprotein (LDL) particles from the blood. 
Although FH, in its heterogenous form, affects 1 in 500 people (86); it can 
generally be treated with HMGCR inhibitors, a class of drugs collectively referred 
to as the statins. However, approximately 1 in 1 million people are affected by 
homozygous FH (hFH) and possess essentially no functional LDLRs. These 
patients manifest severe and widespread atherosclerosis leading to coronary 
events at ages as young as 1-2 years and untreated hFH generally results in 
death due to cardiovascular disease, commonly in the teen years. While 
conventional treatment can extend the life expectancy of hFH patients, longer 
term survival often requires unusual methods, such as liver transplantation or 
repeated plasmapheresis, that are generally not available to many patients. 
Since most common therapies utilized to reduce serum cholesterol levels, such 
as the statins and bile acid sequestrants, ultimately rely upon a secondary 
induction of hepatic LDLRs to mediate the uptake of cholesterol containing 
lipoproteins from the plasma into the liver, their utility in treating hFH is limited. 
Thus new therapeutic options for the treatment of hFH are sorely needed.  
 
Although endogenous thyroid hormones, such as T3, can lower serum 
cholesterol, their use in the treatment of hypercholesterolemia is limited due to 
deleterious cardiac and other side effects. This has led to development of 
thyromimetics, thyroid hormone analogues designed to maintain the beneficial 
effects of thyroid hormones, such as cholesterol reduction and weight loss, 
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without undesirable side effects (87). As a class, thyromimetics have been shown 
to lower serum cholesterol levels in rodents, monkeys, and humans. While it is 
clear that thyroid hormones and thyromimetics reduce serum cholesterol levels, 
the mechanism behind this reduction is less apparent. TR agonists have been 
reported to reduce plasma cholesterol levels via induction of several different 
pathways that include increasing bile acid synthesis via the induction of Cyp7a1 
(38, 40, 41) and increasing reverse cholesterol transport by increasing 
expression of the HDL receptor SR-BI (40, 41). However, the most notable 
rationale has been that thyroid hormones can stimulate expression of the LDLR 
(34, 38, 39). In support of this mechanistic view, all reports describing the use of 
T3 or thyromimetics in LDLR-/- mice have found the compounds to be ineffective 
at lowering plasma cholesterol levels in this genetic background (38, 41), despite 
the same compounds demonstrating efficacy in mice that possessed functional 
LDLRs. 
 
GC-1 is a thyromimetic that has been studied extensively and has been shown to 
lower LDL cholesterol in multiple species (32, 88). A previous report described 
that GC-1 was able to reduce serum cholesterol by 25% in wild-type mice, with 
no accordant increase observed in LDLR levels, and this effect was attributed to 
increases in reverse cholesterol transport mediated by increased expression of 
the HDL receptor, SR-BI (40). Given that GC-1 was able to reduce serum 
cholesterol in the absence of any apparent increase in LDLR levels, it seemed 
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reasonable to determine whether this compound retained at least partial efficacy 
in mice lacking functional LDLRs. Here, we show that the thyroid hormone T3 and 
the thyromimetics GC-1 and KB2115 are potent and effective reducers of serum 
LDL cholesterol in LDLR-/- mice and present evidence to show that this effect is 
related to an increased conversion of cholesterol to bile acids and a subsequent 
increase in bile acid secretion. We propose that thyromimetics may represent a 
novel therapeutic approach to the treatment of hFH.  
 
RESULTS 
GC-1 Lowers Serum Cholesterol in LDLR-/- Mice 
LDLR-/- mice fed a high fat, high cholesterol diet exhibited serum cholesterol 
levels that were elevated approximately 10-fold relative to wild type mice fed a 
similar diet (Figure 2-1A). Somewhat unexpectedly, supplementation of diets with 
the thyromimetic GC-1 triggered a rapid and marked decrease in serum 
cholesterol and triglycerides (Figure 2-1, A and B), with both being reduced to 
about one third of their pre-treatment levels in 7 days. FPLC fractionation of 
cholesterol containing lipoproteins indicated that the reduction in serum 
cholesterol resulted primarily from a reduction in LDL cholesterol (Figure 2-1C), 
as little to no changes were apparent in the cholesterol content of VLDL and HDL 
fractions. Thus, GC-1 can induce dramatic LDL cholesterol-lowering in the 
absence of LDL receptors in mice. 
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Figure 2-1. GC-1 reduces serum cholesterol and triglyceride levels in LDLR-/- mice.  
Male LDLR-/- mice were administered GC-1 (4.8 mg/kg-diet) in a western diet containing 0.2% 
cholesterol or control diet lacking GC-1 (n = 6). Blood samples were collected at the times 
indicated and assayed for serum cholesterol (A) and triglycerides (B). (C) Size exclusion 
fractionation of serum lipoproteins from mice administered GC-1 for 10 days (blood from 5 
animals was pooled for each trace). Data are mean ± s.e.m. *P < 0.05, ***P < 0.001. 
 
GC-1 Does Not Induce Alternative Lipoprotein Receptors, Including SR-BI.  
The majority of cholesterol reduction therapies, including the statins, work via an 
SREBP mediated increase in LDLR levels, which results in increased LDLR-
dependent uptake of LDL cholesterol from the plasma compartment into the liver. 
For example, transgenic mice that overexpress SREBP-1a have reduced serum 
cholesterol levels despite an increased rate of cholesterol synthesis due to a 6-
fold increase in liver cholesterol storage that is mediated via the LDLR (35). To 
assess whether GC-1 caused a similar net transfer of cholesterol from the serum 
into hepatocytes of LDLR-/- mice, perhaps via the induction of alternative hepatic 
lipoprotein receptors, liver cholesterol levels were measured. Total hepatic 
cholesterol content was unaffected by GC-1 and expression levels of alternative 
hepatic lipoprotein receptors were unchanged following GC-1 treatment (Figure 
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2-2, A and B). Thus, the GC-1 dependent reduction in serum cholesterol was not 
due to a net increase in liver cholesterol storage.  
 
 
Figure 2-2. Total hepatic cholesterol content and expression of hepatic lipoprotein 
receptors were unaffected by GC-1 in LDLR-/- mice.  
Hepatic cholesterol and lipoprotein receptor expression were assessed from livers collected from 
LDLR-/- mice treated with GC-1 for 10 days (n = 6). ). Data are mean ± s.e.m. 
 
Several reports have suggested that thyroid hormones and GC-1 reduce serum 
cholesterol by increasing hepatic expression of the HDL receptor, SR-BI, and 
stimulating aspects of reverse cholesterol transport through the HDL pathway 
(40, 41). However, GC-1 treatment did not induce expression of SR-BI at either 
the gene or protein level in LDLR-/- mice (Figure 2-2B and 2-3). Given the 
absence of effects on HDL cholesterol levels and the HDL receptor, SR-BI, our 
data are largely inconsistent with the idea that marked GC-1 dependent 
reductions in LDL cholesterol levels in LDLR-/- mice are related to changes in 
HDL uptake.  
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Figure 2-3. GC-1 does not induce hepatic SR-BI protein. 
SR-BI protein levels were measured from male LDLR-/- mice treated with GC-1 for 10 days (n = 
6). Data are mean ± s.e.m. 
 
GC-1 Strongly Induces Cyp7a1, Resulting in Increased Bile Acid Synthesis 
and Secretion in LDLR-/-Mice.  
Although we were unable to find mechanistic evidence of GC-1 dependent 
increases in cholesterol uptake into the liver, subsequent steps of reverse 
cholesterol transport, in particular numerous mediators of bile acid synthesis and 
excretion, were strongly affected by GC-1 treatment. Hepatic expression of 
Cyp7a1, the enzyme responsible for the rate-limiting step in the synthesis of bile 
acids from cholesterol, was increased 7-fold following GC-1 treatment (Figure 2-
4A). Consistent with the large increase in Cyp7a1 levels, serum levels of 7alpha-
hydroxy-4-cholesten-3-one (C4), a marker of bile acid synthesis and a 
physiologic indicator of Cyp7a1 activity (89), were increased nearly 5-fold 
following GC-1 treatment (Figure 2-4B) and fecal excretion of bile acids was 
increased 2.5-fold (Figure 2-4C). In accordance with increased synthesis of bile 
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acids and an expansion of the bile acid pool, expression levels of I-BABP, a 
reporter of intestinal bile acid levels (90), was increased approximately 3-fold 
(Figure 2-4D). ASBT, which is responsible for reabsorption of bile acids in the 
ileum and whose inhibition has been shown to increase fecal bile acid excretion 
(91), was significantly reduced by GC-1 (Figure 2-4E).  
 
 
Figure 2-4. Effect of GC-1 on bile acid synthesis and fecal excretion.  
Male LDLR-/- mice were administered GC-1 (0.8 mg/kg-diet) in a western diet containing 0.2% 
cholesterol or control diet lacking GC-1. Hepatic Cyp7a1 expression (A) and serum C4 levels (B) 
were measured after 10 days of treatment. (C) Feces were collected from days 5-8 of treatment 
and analyzed for bile acids. (D,E) Intestinal expression of I-BABP and ASBT of mice treated with 
GC-1 for 10 days (n = 4-5 per group) (*P<0.05, **P<0.01, ***P<0.001) 
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Although hepatic ABCB4, which is involved in bile acid and phospholipid 
excretion, was induced by GC-1, other hepatic transporters commonly implicated 
in cholesterol uptake and efflux, were unaltered (Figure 2-5A). Intestinal 
transporters including the LXR and FXR target genes ABCG5/8 (92), and 
OSTa/b (93), whose induction has been linked to increased cholesterol and bile 
efflux were either unaltered or decreased (Figure 2-5B). Although decreased 
expression of intestinal ABCG5/8 would be expected to increase the uptake of 
neutral sterols (92, 94), the net excretion of neutral sterols was unaltered (Figure 
8C), indicating that compensatory mechanisms, such as the actions of hepatic 
ABCG5/8 whose levels were unchanged, offset any increase in the uptake of 
neutral sterols. Collectively, these data suggest that the induction of Cyp7a1 by 
GC-1 strongly affects bile acid synthesis and excretion pathways evoking a net 
flux of cholesterol from the plasma compartment into the bile pool as bile acids, 
which are then excreted in the feces.  
 
Figure 2-5. Effect of GC-1 on expression of hepatic and intestinal transporters involved in 
cholesterol homeostasis.  
Gene expression of cholesterol transporters in liver (A) or ileum (B) sections of mice treated with 
GC-1 for 10 days (n = 4–5). Feces were collected from days 5-8 of treatment and analyzed for 
neutral sterols. Data are mean ± s.e.m. ***P < 0.001. 
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TR Agonists Reduce Serum Cholesterol More Effectively Than Statins in 
LDLR-/- Mice.  
 
Figure 2-6. Effects of T3, thyromimetics, and statins on serum cholesterol in LDLR-/- mice.  
Male LDLR-/- mice were administered GC-1 (0.8 mg/kg-diet) in a western diet containing 0.2% 
cholesterol or control diet lacking GC-1 (n = 4–5). Hepatic Cyp7a1 expression (A) and serum C4 
levels (B) were measured after 10 days of treatment. (C) Feces were collected from days 5-8 of 
treatment and analyzed for bile acids. Intestinal expression of I-BABP (D) and ASBT (E) of mice 
treated with GC-1 for 10 days. Data are mean ± s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001. 
 
To determine whether cholesterol reduction in LDLR-/- mice was a property 
unique to GC-1 we compared the efficacy of GC-1 to that of another 
thyromimetic, KB2115, the thyroid hormone T3, as well as atorvastatin, the last of 
which represents one of the most powerful statin drugs (95). Mice treated with 
either GC-1, KB2115, or T3 for 10 days exhibited similar levels of cholesterol 
reduction (Figure 2-6A), indicating that the ability to significantly reduce serum 
cholesterol in the absence of functional LDLRs extends beyond GC-1, and is 
perhaps a general capability of all TR agonists. All three TR agonists increased 
Cyp7a1 expression between 4 and 7-fold and evoked a correspondent increase 
in bile acid synthesis, as indicated by increased plasma C4 levels (Figure 2-6, B 
and C). Consistent with the idea that the statins and TR agonists utilize distinct 
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mechanisms of cholesterol reduction, T3 and the thyromimetics were more 
effective than atorvastatin at reducing serum cholesterol in LDLR-/- mice and only 
the TR ligands increased bile acid synthesis, as indicated by serum C4 levels. 
Expression levels of hepatic lipoprotein receptors and genes involved in 
cholesterol homeostasis were affected similarly by all TR agonists (Figure 2-7, A 
and B). Notably, SR-BI was repressed by all treatments, further arguing against 
SR-BI-mediated reverse cholesterol transport playing a key role in the observed 
cholesterol reduction.  
 
 
Figure 2-7. Effects of T3, thyromimetics on lipoprotein receptors and cholesterol 
homeostasis genes in LDLR-/- mice.  
Changes in expression of hepatic of lipoprotein receptors (A) and regulatory genes (B) were 
measured from LDLR-/- mice fed a western diet containing 0.2% cholesterol and treated with 
either 0.3 mg/kg T3, 0.3 mg/kg KB2115, 0.3 mg/kg GC-1, or vehicle administered via i.p. injection 
for 10 days (n = 5). Data are mean ± s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001. 
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TR Agonists Reduce Plasma Lipids Despite Increased Hepatic VLDL and 
ApoB Secretion.  
 
Figure 2-8. GC-1 increases hepatic triglyceride and ApoB secretion rates.  
Male LDLR-/- mice were administered GC-1 (4.8 mg/kg-diet) in a western diet containing 0.2% 
cholesterol or control diet lacking GC-1 for 10 days (n = 3–4). After a 4 h fast, mice were injected 
with poloxamer 407 (P-407) and [35S]-methionine. Blood was collected at time 0, 1, and 2 hr and 
assayed for triglycerides (TG) (A), ApoB-100 (B), and ApoB-48 (C). Data are mean ± s.e.m. *P < 
0.05. 
 
That hepatic cholesterol levels did not decrease despite markedly increased 
rates of bile acid synthesis and fecal excretion suggests that a compensatory 
mechanism must be responsible for preventing a reduction in hepatic cholesterol. 
Treatment with T3, GC-1, or KB2115 lowered hepatic expression of the lipogenic 
regulators SREBP-1c and SREBP-2 and decreased ApoB mRNA levels, leading 
us to hypothesize that the decreased hepatic secretion of ApoB containing 
lipoproteins may account for the reduced levels of serum lipids as well as the 
maintenance of hepatic cholesterol. The rate of accumulation of triglycerides and 
nascent ApoB in the blood was determined following the coadministration of 
[35S]-methionine and the lipoprotein lipase inhibitor poloxamer 407. Hepatic 
secretion of both triglycerides and [35S]-methionine-labeled ApoB increased 
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strongly following GC-1 treatment (Figure 2-8). Although unexpected, these 
results are consistent with previous reports demonstrating that T3 treatment and 
Cyp7a1 overexpression increase hepatic ApoB and triglyceride secretion (96–
98), despite both TH action and Cyp7a1 activity being clearly associated with net 
reductions in serum ApoB containing lipoproteins. Thus, the relationship between 
thyroid hormones and their hepatic target Cyp7a1 with serum lipoprotein levels is 
likely complex. 
 
GC-1 Affects Bile Acid Synthesis Similarly in Mice That Possess Functional 
LDLRs.  
 
Figure 2-9. GC-1 treatment elicits similar effects in mice with functional LDLRs.  
Male C57 mice fed a western diet containing 0.2% cholesterol were administered 0.3 mg/kg/d 
GC-1 or vehicle via i.p. injection for 10 days (n = 4–5). Changes in serum cholesterol (A), hepatic 
gene expression (B), serum C4 levels (C) were measured. Data are mean ± s.e.m. *P < 0.05. 
 
In order to assess whether TR agonists utilize distinct mechanisms of cholesterol 
reduction in LDLR-/- mice and wild-type mice that possess functional LDLRs, C57 
mice fed a western diet were treated with either GC-1 or T3. GC-1 treatment 
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resulted in a complete normalization of serum cholesterol, markedly increased 
hepatic Cyp7a1 expression and rate of bile acid synthesis, and altered hepatic 
gene expression (Figure 2-9, A-C) in a manner remarkably similar to that seen 
when LDLR-/- mice were administered GC-1 (Figure 2-6).  
 
 
Figure 2-10. GC-1 Treatment elicits similar effects in mice with functional LDLRs.  
Changes in LDLR (A) and SR-BI protein (B) were measured from male C57 mice fed a western 
diet containing 0.2% cholesterol were administered 0.3 mg/kg/d GC-1 or vehicle via i.p. injection 
for 10 days (n = 4–5). Data are mean ± s.e.m. *P < 0.05. 
 
GC-1 led to a significant down-regulation of the hepatic lipoprotein receptors 
LDLR and SR-BI, at both the gene and protein level (Figure 2-9B and Figure 2-
10), making it unlikely that cholesterol uptake by either receptor was responsible 
for the decrease in serum cholesterol. Treatment with T3 at a level similar to that 
tolerated by LDLR-/- mice proved to be toxic to this strain, precluding detailed 
analysis of the data. Qualitatively, however, T3 appeared to act in a manner 
analogous to GC-1 (Figure 2-11). These data suggest that the hepatic induction 
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of the lipoprotein receptors LDLR and SR-BI is likely unnecessary for the 
cholesterol lowering effects of TR activation.  
 
 
Figure 2-11. T3 reduces serum cholesterol and affects bile acid synthesis in a fashion 
similar to GC-1.  
Male C57Bl6 Mice were treated with 0.3 mg/kg-day T3 administered via i.p. injection for 10 days, 
which proved to be toxic to this strain, resulting in morbidity or mortality to most treated animals. 
Serum cholesterol (A), hepatic gene expression (B) and serum C4 levels (C) were measured for 
the surviving animals (n = 2). Data are mean ± s.e.m. Statistical analysis was not performed due 
to the small number of animals. 
 
Discussion 
In this study, we report that the thyroid hormone T3 and two TRβ-selective 
thyromimetics, GC-1 and KB2115, bring about marked reductions in serum total 
and LDL cholesterol in LDLR-/- mice, which lack functional LDL receptors. Our 
results suggest that cholesterol reduction in these mice is mediated primarily via 
the induction of Cyp7a1, leading to increased fecal excretion of cholesterol as 
bile acids, and does not require the action of alternative lipoprotein receptors 
such as the HDL receptor SR-BI. This finding suggests that current models, 
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which generally suggest that the effects of thyroid hormones and thyromimetics 
upon serum cholesterol are mediated principally by the increased expression of 
the hepatic lipoprotein receptors LDLR and SR-BI, are, at best, incomplete.  
 
The actions of many commonly used cholesterol lowering therapeutics, such as 
the statins, bile sequestrants, and the NPC1L1 inhibitor ezetimibe, are mediated 
in large part by increased expression of LDLRs. Since thyroid hormones have 
been shown to induce the LDLR similarly, it is not surprising that increased LDLR 
expression is the mechanism most common ascribed to cholesterol reduction by 
thyroid hormones (28). Although several other mechanisms of cholesterol 
reduction by thyroid hormones have been proposed, the lack of prior reports 
demonstrating that thyroid hormones and thyromimetics can reduce serum 
cholesterol in the absence of LDLRs has led to the inference that cholesterol 
reduction by TR agonists is primarily an LDLR-dependent effect. Results of the 
current study reveal this assumption to be incorrect and demonstrate that TR 
activation can reduce serum cholesterol via an LDLR-independent mechanism. 
 
Of the potential LDLR-independent mechanisms of cholesterol reduction by TR 
activation, the most commonly proposed is induction of the HDL receptor, SR-BI, 
leading to an increased rate of reverse cholesterol transport (40). While several 
reports have indicated that thyroid hormones can stimulate SR-BI expression, we 
do not believe that this effect plays an important role in cholesterol reduction in 
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LDLR-/- mice. First, we did not observe changes in SR-BI expression, at either 
the transcript or protein level, in LDLR-/- or C57 mice. Secondly, cholesterol 
reduction in LDLR-/- mice is largely restricted to the LDL fraction and there is little 
change in HDL cholesterol following thyromimetic treatment. Finally, while SR-BI 
induction and increased reverse cholesterol transport appears a quite reasonable 
mechanism by which thyroid hormones could reduce cholesterol in most rodent 
species, which maintain the majority of their serum cholesterol as HDL 
cholesterol, it is difficult to rationalize how such a large decrease in LDL 
cholesterol levels could result from this mechanism in LDLR-/- mice, for which 
nearly all serum cholesterol is carried via LDL particles and have limited ability to 
transfer cholesterol between LDL and HDL particles due to their lack of 
cholesteryl ester transferase protein activity. 
 
Instead, our results suggest that the TR agonists tested here reduce serum 
cholesterol levels in LDLR-/- mice by strongly inducing Cyp7a1, resulting in 
increased cholesterol to bile acid conversion and increased fecal bile acid 
excretion. That similar effects on Cyp7a1 expression and bile acid synthesis 
were observed in wild-type C57 mice, in the absence of LDLR or SR-BI 
induction, suggest to us that the reductions in serum cholesterol brought about 
by thyroid hormones and TR activation may be mediated primarily via the 
induction of Cyp7a1. Indeed, the effects elicited by TR activation correspond 
nearly wholly with those seen in mice following hepatic overexpression of 
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Cyp7a1. Increased Cyp7a1 activity has been demonstrated to be sufficient to 
lower plasma cholesterol levels in LDLR-/- mice and WHHL rabbits, both of which 
lack functional LDLRs (99–101). In accordance with our findings, this action did 
not require the induction of alternative hepatic lipoprotein receptors or hepatic 
cholesterol efflux transporters (100). The TR agonists studied did not reduce 
hepatic cholesterol levels despite strongly increasing hepatic excretion of bile 
acids. This is presumably due to increase/;d hepatic synthesis of cholesterol, 
since Cyp7a1 overexpression has been shown to evoke a compensatory 
increase in de novo cholesterol synthesis, preventing a decrease in hepatic 
cholesterol (101, 102) and T3 treatment has been shown to have similar effects 
on hepatic cholesterol synthesis (103). 
 
The mechanism by which Cyp7a1 induction affects plasma lipoproteins appears 
to be multivariate and is not well understood. Consistent with Cyp7a1 being the 
primary mediator behind the lipid lowering actions of TR activation, the manner 
by which the TR agonists tested reduce serum cholesterol and triglycerides 
appears to be correspondingly complex. Similar to prior reports, which have 
shown that T3 and Cyp7a1 overexpression increase hepatic triglyceride and 
VLDL secretion (96–98, 104), GC-1 treatment elicited an increase in the 
secretion of triglycerides and ApoB despite markedly decreasing total serum 
triglyceride and LDL cholesterol levels. This paradoxical effect of hepatic Cyp7a1 
activation may help explain the divergent reports relating TR agonist treatment 
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with serum triglyceride levels (38, 40, 88). Indeed, we have found that, in contrast 
to the results presented here, the treatment of non-hypertriglyceridemic mice with 
thyromimetics increases serum triglyceride levels. 
 
As Cyp7a1 has been shown previously to be a TR regulated gene in mice (105) 
and rats (106), it is perhaps not surprising that these compounds increased 
Cyp7a1 expression. However, the magnitude of the cholesterol reduction brought 
about by Cyp7a1 induction was quite unanticipated in light of the fact that the 
aforementioned studies demonstrating the ability of Cyp7a1 induction to reduce 
serum cholesterol utilized transgenic and viral over-expression methods. 
Thyromimetics could represent a novel avenue for treatment of defects in 
cholesterol metabolism associated with hFH. In accordance with animal studies, 
where Cyp7a1 overexpression leads to reduced serum cholesterol and 
triglycerides and increased bile acid excretion, human deficiency in Cyp7a1 
results in elevated serum cholesterol and triglycerides and an appreciably 
reduced rate of bile acid excretion (107) suggesting that increasing Cyp7a1 
expression may be a viable LDLR-independent pharmacological strategy to 
reduce serum cholesterol in man. The regulation of Cyp7a1 has been reported to 
differ between rodents and humans (108), implying that these results may not 
translate to clinical studies. However, similar to our findings here, KB2115 has 
been shown to strongly stimulate bile acid synthesis in humans (109), increasing 
serum C4 levels by over 100%, indicating that a similar mechanism may play a 
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role in the cholesterol lowering effects of TR activation in man. This potential 
ability to reduce cholesterol via a mechanism distinct from the statin drugs may 
also provide a rationale behind the clinical efficacy of KB2115, which has been 
shown to act additively when administered concurrently with statins, further 
reducing total and LDL cholesterol levels when given to hypercholesterolemic 
patients already being treated with statins (110). 
 
In conclusion, the thyroid hormone T3 and the thyromimetics GC-1 and KB2115 
reduce serum cholesterol via an LDLR-independent mechanism that appears to 
be mediated primarily by the induction of Cyp7a1 and increased bile acid 
synthesis, making it distinct from that of most other cholesterol lowering 
therapies. This class of compounds may have value in treating high cholesterol, 
especially for diseases such as hFH, for which LDLR induction is minimally 
effective. Given the lack of effective treatment options for affected hFH patients 
and the severity of the disease, thyromimetics such as GC-1 and KB2115 may 
warrant evaluation for their ability to lower serum cholesterol in this population. 
 
Materials and Methods 
Animals 
Male LDLR-/- and C57 mice were obtained from Jackson Labs (Maine) and 
housed in a temperature-controlled environment with 12 h light/dark cycles and 
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fed standard irradiated rodent chow ad libitum (TD.2918, Harlan Teklad). All mice 
used in the studies were male aged-matched of 4 months of age. Prior to 
treatment mice were fed a western diet containing 0.2% cholesterol (D12079B, 
Research Diets) for 12 weeks. Unless otherwise noted, at 6 week-old mice were 
fed a western diet containing 0.2% cholesterol (D12079B, Research Diets) for 12 
weeks. All animal experiments were approved by the Methodist Hospital 
Research Institute Institutional Animal Care and Use Committee. 
 
Animal Treatments 
Triiodothyronine (T2877; Sigma), KB2115 (10011054; Cayman), and atorvastatin 
(sc-337542; Santa Cruz Biotechnology) dissolved in DMSO were administered 
by intraperitoneal injection. GC-1 was administered by either intraperitoneal 
injection or admixed in the diet (western diet, Research Diets) and provided ad 
libitum. Details of each experiment are described in figure legends. In all cases, 
animals in the control group received the appropriate vehicle solutions and diets 
identical to the treatment groups. 
 
Lipid And Lipoprotein Analysis 
For hepatic lipid analysis, liver tissue was homogenized and total lipids were 
extracted from liver using a Folch solution (chloroform/methanol, 2:1), 
precipitated with sodium chloride, dried and resuspended in 2% Triton X-100 
PBS. Plasma and tissue lipid extracts were assayed for cholesterol and 
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triglycerides using commercial kits (Thermo Scientific). For lipoprotein profiling 
pooled plasma was separated by FPLC using two Superose 6 columns (GE 
Healthcare) linked in tandem, 300 ml fractions were collected and lipid levels 
were analyzed in each fraction using a fluorescence enzymatic assay (Cayman).  
 
Plasma C4 (7α-hydroxy-4-cholesten-3-one) Levels 
Plasma 7α-hydroxy-4-cholesten-3-one levels were measures as described (88) 
with modifications. Deuterium labeled C4 (Santa Cruz Biotechnology) internal 
standard was added to 10 µl of plasma, followed by ammonium sulfate and 
acetonitrile precipitation, supernatant was dried and resuspended in methanol. 
Plasma C4 levels were measured using LC-ESI-MS/MS (111) on an Acquity® 
UPLC system (Waters Corp) and XevoTQ® mass spectrometer (Waters Corp) 
operated in the MRM mode using positive ion electrospray conditions. C4 levels 
were normalized to total cholesterol levels. 
 
Fecal Sterol Analysis 
Mice were acclimated to metabolic cages prior to a 72-hour feces collection. 
Dried feces were boiled in alkaline methanol (1 M NaOH/Methanol, 1:3) after 
addition of 5α-cholestane as an internal standard for neutral sterol analysis. After 
cooling to room temperature, neutral sterols were extracted using petroleum 
ether, the combined organic layers was dried and redissolved in hexane for gas 
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chromatography analysis. Total bile acids in the aqueous layer were measured 
using a spectrophotometric enzymatic assay (Diazyme). 
Immunoblotting 
Liver tissue was homogenized in tissue extraction reagent (Invitrogen) containing 
complete protease inhibitor (Roche Diagnostics). Equivalent amounts of total 
protein were separated by SDS-PAGE, transferred to polyvinylidene difluoride 
membranes and probed with anti-SR-BI (ab3), anti-LDLR (ab52818) or anti-β-
actin (6267) antibody (Abcam) and secondary conjugated-HRP anti-rabbit or (sc-
2004) anti-mouse (sc-2005) antibody (Santa Cruz Biotechnology). The proteins 
were visualized using Amersham ECL Western Blotting Detection Regents (GE 
Healthcare) and autoradiography. 
 
RNA Extraction and Real-time qPCR 
Total RNA was extracted and isolated using Qiazol and RNeasy Mini Kit 
according to manufacturer’s protocol (Qiagen). First strand cDNA was 
transcribed from 2.5 mg of total RNA using SuperScript VILO cDNA Synthesis Kit 
(Invitrogen). TaqMan real-time PCR reactions were performed on a LightCycler 
480 Real-Time PCR system (Roche) and relative mRNA levels were calculated 
by comparative Ct method using β-actin as the internal control. TaqMan 
primer/probe sets supplied by Applied Biosystems were used (Assay IDs are 
available upon request). 
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Hepatic Triglyceride and ApoB Secretion Rate Determination 
Triglyceride and apoB secretion rate was performed as previously described 
(112). Mice fasted for 4 h were injected with poloxamer 407 (1000 mg/kg) and 
200 µCi of [35S]-methionine. Blood samples were collected prior to injection and 
at 60 and 120 min following. The concentration of serum triglycerides was 
measured using commercial kits. For ApoB secretion rate, plasma samples were 
separated on a 3-8% SDS-PAGE gel. The gel was dried under vacuum and 
exposed to x-ray film. Bands representing newly synthesized [35S]-labeled ApoB 
were excised and counted via liquid scintillation.  
 
Statistical Analysis 
All results are expressed as mean ± SEM. Statistical analysis was performed 
using GraphPad Prism software. Comparisons of groups were performed using 
Student’s T-test. A p-value of less than 0.05 was considered significant.  
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CHAPTER 3 THYROID HORMONE RECEPTOR 
AGONISTS ELICIT A FUNCTIONAL CONVERSION OF 
WHITE TO BROWN FAT 
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Functional conversion of white adipose tissue (WAT) into a tissue with brown 
adipose tissue (BAT)-like activity may be an important strategy to combat obesity 
and control type 2 diabetes. We demonstrate that thyroid hormone receptor (TR) 
activation by T3 or the synthetic agonist GC-1 induces a program of adaptive 
thermogenesis and uncoupled respiration in subcutaneous WAT that is 
correspondent with the amelioration of obesity and insulin resistance. Surgical 
denervation of BAT has no effect on systemic thermogenesis, and all 
thermogenesis is lost in lean mice that possess little subcutaneous WAT, 
suggesting that induction of thermogenesis is mediated by WAT. These data 
demonstrate that TR activation can elicit facultative thermogenesis in WAT, a 
previously unrecognized component of TR-mediated thermogenesis, and 
establish the profound pharmacological potential of WAT browning.  
 
INTRODUCTION 
Obesity is an accelerating worldwide health crisis associated with co-
morbidities that include diabetes, hyperlipidemia, and hypertension. The World 
Health Organization estimates that over 500 million adults worldwide are obese 
and attributes 2.8 million annual deaths to obesity associated disease (113). 
Obesity is caused by a chronic imbalance of excess caloric intake relative to 
expenditure (114, 115). The excess energy, which is stored as lipid within white 
fat, leads to an expansion of this tissue. While nearly everyone is familiar with 
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WAT, typically referred to simply as ‘fat’, there is far less appreciation for BAT, a 
unique type of adipose tissue. By uncoupling oxidative metabolism from ATP 
generation, BAT has the relatively unique capacity to perform adaptive 
thermogenesis, the conversion of excess energy to heat. This ability gives BAT 
high metabolic potential; when activated, BAT can double metabolic rate in 
rodents (116). Thus, while WAT serves primarily to store excess energy, BAT 
can dispose of excess energy by converting it to heat (53, 117).  
 
Since BAT-mediated adaptive thermogenesis is inherently anti-obesogenic (66, 
67), there has long been an interest in harnessing this action to treat obesity 
(118). However, until recently, it was generally accepted that adult humans did 
not possess brown fat (53, 115) implying that the direct targeting of BAT was not 
a viable therapeutic approach. Instead, it was questioned whether WAT could be 
induced to become more BAT-like (119), thus increasing energy expenditure. 
The prospect of doing so was bolstered by evidence of BAT-like, or 'beige' cells 
appearing within WAT depots in response to cold exposure or treatment with β-
adrenergic agonists (77, 79, 120). Although tantalizing, the physiological 
relevance of these beige cells was unclear and it was not apparent how to 
harness this effect clinically (121).  
 
Two recent events have led to a strong renewed interest in utilizing adaptive 
thermogenesis to combat obesity. First, several groups have reported the 
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existence of active brown fat in adult humans (68–72). Furthermore, BAT activity 
in humans appears to correlate with resistance to obesity (69, 70). Second, 
numerous reports in the past year have demonstrated the ability to impart BAT-
like function within WAT depots of rodents, a process often referred to as 
'browning' (21–24). While these examples have shown that the induction of BAT-
like adaptive thermogenesis in WAT can have anti-obesogenic and anti-diabetic 
effects, the magnitude of these effects have generally been modest despite the 
use of genetically engineered mice, leading some to question the 
pharmacological potential of browning (122).  
 
It is well established that TR signaling is involved in the regulation of 
thermogenesis, body temperature (42), and energy balance (32). In humans, 
hypothyroidism is associated with hypersensitivity to cold while hyperthyroid 
individuals have difficulty tolerating heat (18). Loss of TR signaling in rodents, 
either by ablation of TRs or by thyroidectomy, results in decreased body 
temperature and cold intolerance (10, 123). Although TR-mediated 
thermogenesis is generally attributed to BAT, the relationship between TR 
activation and thermogenesis is complex and has not been fully resolved (42). 
Here we report that TR activation by the synthetic agonist GC-1 and the 
endogenous ligand T3 elicits a BAT-like program of adaptive thermogenesis and 
uncoupled respiration in subcutaneous WAT (scWAT). This action, which is 
accompanied by marked increase in metabolism and dramatic fat loss, appears 
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to be mediated principally by WAT, suggesting that the browning of WAT may 
represent an unappreciated component of TR-induced thermogenesis.  
 
RESULTS 
The TR Agonist GC-1 Elicits a BAT-like Program of Adaptive 
Thermogenesis in scWAT 
To explore how TR agonists induce thermogenesis in vivo, we treated genetically 
obese (ob/ob) mice with the synthetic agonist GC-1 and profiled changes in the 
expression of markers of thermogenesis and uncoupled respiration (Ucp1, 
Ppargc1a, Prdm16, Elovl3, Cidea, Pparg, Cebpb, and Dio2) (53, 73, 124–126) 
and mitochondrial function (Tfam, Nrf1, Cycs, Cox4) (114, 126) in BAT, 
epididymal WAT, and scWAT depots (Figure 3-1 A-D). A similar panel of 
markers, including genes involved in oxidative metabolism or previously 
implicated in muscle-mediated thermogenesis (Serca1 and Serca2, Ucp3, Cpt1a 
and Cpt1b, Mcad, PDK4, Myh7, Myh1, and Myh4) (127), was used to monitor 
changes in muscle gene expression (Figure 3-1D). Somewhat surprisingly, GC-1 
significantly repressed all markers in BAT (Figure 3-1A). In contrast, the 
expression of all genes was strongly induced in scWAT, with levels of Ppargc1a, 
Elovl3, Cidea, Dio2, Cox5a, and Cebpb increased by over 10-fold, while Ucp1 
levels were increased by over 100-fold (Figure 3-1B). Estimation of absolute 
transcript levels suggested that, following GC-1 treatment, Ucp1 mRNA levels in 
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scWAT were similar to those found in BAT (Figure 3-2). In epididymal WAT, 
Ucp1 levels were increased, although expression of other genes in the 
thermogenic program were either decreased or unchanged (Figure 3-1C). GC-1 
altered expression levels of Serca2, Ppargc1a, Cox5a, and Myh4 in muscle, 
although expression of other genes including Ucp1 was unchanged and the 
magnitude of the observed changes was small relative to the alterations seen in 
 
Figure 3-1. Thermogenic gene expression in BAT, scWAT, epiWAT and muscle. 
Male ob/ob mice were fed standard chow with or without admixed GC-1 for 21 days (n = 4–6). At 
the end of day 21, mice were sacrificed and tissues were collected. Thermogenic gene 
expression was measured in brown adipose tissue (BAT) (A), subcutaneous white adipose tissue 
(scWAT) (B), epididymal white adipose tissue (epiWAT) (C) and gastrocnemius muscle (d) of GC-
1 treated and untreated mice. Data are mean ± s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001. 
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scWAT and BAT (Figure 3-1D). These data suggest that the TR agonist GC-1 
induces the full genetic program of thermogenesis and uncoupled respiration in 
scWAT.  
 
 
Figure 3-2. Similar levels of Ucp1 transcript in scWAT of GC-1 as BAT. 
Relative Ucp1 transcript levels in epiWAT, subQWAT, and BAT (n = 4–6). Data are mean ± 
s.e.m. *P < 0.05, ***P < 0.001. 
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Since UCP1 is generally considered the key mediator of uncoupled respiration in 
adipocytes, we investigated how GC-1 affected UCP1 protein levels within the 
various adipose tissue depots. While UCP1 protein levels were unaltered in BAT, 
the effect in scWAT was striking. UCP1 protein, which was undetectable in the 
scWAT of untreated mice, was increased at least 100-fold, reaching a level 
equivalent to 40% of that found in BAT (Figure 3-3). UCP1 levels were 
undetectable in epididymal WAT of both treated and untreated animals.  
 
Figure 3-3. GC-1 induces an increase in UCP1 protein in scWAT. 
UCP1 protein expression in epiWAT, scWAT, and BAT of GC-1 treated and untreated mice (n = 
4–6). Data are mean ± s.e.m. ***P < 0.001. N.D., not detectable. 
 
Histological examination of adipose tissue depots revealed striking morphological 
changes in the scWAT of GC-1-treated mice (Figure 3-4). Subcutaneous white 
adipocytes of treated mice were smaller and approximately 40% of the cells 
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acquired multilocular lipid droplets, both features common to brown adipocytes 
(77, 128). Conversely, adipocytes from the BAT depot of treated mice were 
larger with decreased multilocularity. Adipocytes of epididymal WAT exhibited 
little morphological change. To further investigate changes in the metabolic 
 
Figure 3-4. GC-1 induces mutlilocular lipid droplets in scWAT. 
Representative images of epiWAT, scWAT, and BAT were stained with H&E. Scale bar, 100 µm. 
parameters of various adipose tissue depots, we measured mitochondrial DNA 
content (Figure 3-5A) and citrate synthase activity as well as the respiration rate 
of scWAT (Figure 3-5C). Following GC-1 treatment, mitochondrial DNA and 
citrate synthase increased substantially in scWAT (Figure 3-5B). No changes 
were observed in epididymal WAT or BAT. Basal respiration was doubled in 
scWAT of GC-1-treated mice (Figure 3-5C). Since SNS stimulation is required for 
activation of the adaptive thermogenic program, we measured norepinephrine 
levels in BAT and scWAT. Norepinephrine levels, which were substantially 
decreased in BAT of GC-1-treated mice, increased by 48% in scWAT (Figure 3-
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5D). Collectively, GC-1 induces genes involved in adaptive thermogenesis, 
induces mitochondrial biogenesis, increases UCP1 protein, increases metabolic 
rate, and elicits morphological changes in scWAT that are consistent with a BAT-
like phenotype, indicating that GC-1 imparts brown fat-like function to scWAT. 
 
 
Figure 3-5. GC-1 induces increase in mitochondria and respiration in scWAT. 
Mitochondrial DNA content (A) and citrate synthase activity (B) were measured in epiWAT, 
scWAT, and BAT. (C) Oxygen consumption rate in scWAT of GC-1 treated and untreated mice. 
(D) Norepinephrine content in BAT and scWAT of GC-1 treated and control mice. Data are mean 
± s.e.m, n = 4–6. ***P < 0.001. 
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GC-1-induced Browning of scWAT Coincides with Marked Thermogenesis 
and Metabolic Elevation 
 
 
Figure 3-6. GC-1 induces an increase in metabolic rate and body temperature. 
Male ob/ob mice fed diets with or without GC-1 were monitored in metabolic cages (n = 4). 
Metabolic rates were measured by indirect calorimetry at 15 min intervals (A) and the average 
metabolic rate was assessed over a 72-h period (b). Body temperature was measured after 21 
days of treatment (n = 4). Data are mean ± s.e.m. ***P < 0.001. 
 
Several recent reports have demonstrated the capacity to induce a program of 
brown fat-like thermogenesis in WAT (73–76). These reports have almost 
universally suggested that the observed WAT-mediated thermogenesis was 
sufficient to elicit anti-obesity and anti-diabetic actions (73, 75, 129). To examine 
metabolic effects that coincided with the induction of brown-fat-like function in 
WAT, we monitored body temperature and used indirect calorimetry to measure 
changes in metabolic rate that accompanied GC-1 treatment. GC-1 treatment 
was found to raise mean metabolic rate by nearly 60% (Figure 3-6, A and B), and 
increased body temperature by 3.8°C (Figure 3-6C), an increase large enough to 
52 
be readily apparent while handling the animals. The induction of thermogenesis 
 
Figure 3-7. Dramatic weight and fat loss in ob/ob mice treated with GC-1. 
(A) Representative images were taken of GC-1 treated (right) and untreated (left) mice after 21 
days of GC-1. (B) Body fat monitored over the duration of treatment (n = 4). Data are mean ± 
s.e.m. ***P < 0.001. 
was accompanied by marked weight and fat loss (Figure 3-7, A and B). GC-1 
treatment did not alter food intake and treated mice were less active than 
untreated controls, indicating that weight loss resulted solely from increased 
metabolic rate (Figure 3-8, A and B). Lean mass was found to increase following 
 
Figure 3-8. No change in food intake or physical activity. 
Food intake (A) and ambulatory activity (B) were assessed and averaged over a 3-day period (n 
= 4). Data are mean ± s.e.m. 
GC-1 treatment (Figure 3-9A), indicating that weight loss was due exclusively to 
a loss of adiposity. GC-1 treatment also led to a rapid and substantial decrease 
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in the respiratory exchange ratio (RER), with values approaching the theoretical 
minimum of 0.7 (Figure 3-9B), indicating that GC-1 treatment elicited a significant  
shift from the utilization of carbohydrates to fatty acids as substrate in oxidative 
metabolism. The change in RER is consistent with reports demonstrating that 
uncoupling of oxidative phosphorylation by either chemical uncouplers (130) or 
non-shivering adaptive thermogenesis (131) increases the oxidation of fatty acids 
relative to carbohydrates. 
 
 
Figure 3-9. Weight loss is due solely to loss of adiposity. 
(A) Lean mass was monitored in treated and untreated mice over the duration of treatment. (B) 
Respiration exchange ratio was measured from the ratio of V(CO2) produced to V(O2) consumed 
(n = 4). Data are mean ± s.e.m. *P < 0.05. 
 
Leptin-deficient mice are hypothermic due to defects in adaptive thermogenesis, 
resulting in depressed body temperature and intolerance to cold (132). Since 
GC-1 treatment normalized the body temperature of ob/ob mice (Figure 3-10), 
we questioned whether GC-1-induced thermogenesis could also restore cold 
54 
tolerance to these mice. Untreated mice exhibited pronounced shivering and 
piloerection (i.e. goosebumps), both expected physiological responses, almost 
immediately upon exposure to 4°C. Additionally, the body temperature of 
untreated animals was found to decrease sharply when challenged with cold 
(Figure 3-10). Conversely, GC-1-treated animals experienced no decrease in 
body temperature after 15 hours at 4°C. Remarkably, treated animals exhibited 
no apparent shivering or piloerection, suggesting that the program of adaptive 
thermogenesis elicited by GC-1 obviated the need for shivering, generally a key 
component of heat generation in response to cold (133).  
 
Figure 3-10. GC-1 rescues thermogenic effect of ob/ob mice. 
Body temperature was measured during a cold tolerance test after 21 days of GC-1 treatment (n 
= 4). Data are mean ± s.e.m. ***P < 0.001. 
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Figure 3-11. Improved insulin sensitivity assessed by hyperinsulinemic-euglycemic clamp. 
Fasting blood glucose (A) and glucose infusion rate (B) were measured during a 
hyperinsulinemic-euglycemic clamp experiment on days 10-12 of treatment (n = 6). (C) Basal 
glucose production rate was discerned from blood samples collected prior to insulin infusion. 
Glucose disposal rate (D), and hepatic glucose production rate (E) were during hyperinsulinemic-
euglycemic clamp for GC-1-treated and control mice. Data are mean ± s.e.m. **P < 0.01, ***P < 
0.001. 
 
To determine whether GC-1-induced adaptive thermogenesis affected insulin 
sensitivity and glycemic control, we conducted a hyperinsulinemic-euglycemic 
clamps study as well as a glucose tolerance test. GC-1 treatment normalized 
fasting glucose levels, notably increased glucose infusion rate, and led to 
improvements in basal glucose production, glucose disposal rate, and hepatic 
glucose disposal (Figure 3-11, A-E); all indicative of substantially increased 
insulin sensitivity. GC-1-treated mice also exhibited markedly improved glycemic 
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control (Figure 3-12, A and B). Thus, the metabolic effects of GC-1 include 
marked anti-diabetic actions. Collectively, these results suggest that TR 
activation by GC-1 strongly induces a program of non-shivering adaptive 
thermogenesis which results in metabolic increase that ameliorates obesity and 
insulin resistance and is sufficient to compensate fully for thermogenic defects 
inherent to ob/ob mice.  
 
 
Figure 3-12. Increases glucose tolerance of control and GC-1 treated ob/ob mice. 
Glucose tolerance test (A) and area under the curve quantification (B) of treated and untreated 
ob/ob mice was assessed at day 21 (n = 5–6). Data are mean ± s.e.m. **P < 0.01, ***P < 0.001. 
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GC-1 Mediated Adaptive Thermogenesis is Independent of BAT Activity 
 
Figure 3-13. 18F-FDG PET/CT imaging of control and GC-1 treated ob/ob mice. 
Representative PET-CT image of 18F-FDG uptake in BAT (arrowheads) and scWAT (*) in 
untreated (left) and treated (right) ob/ob mice. 
 
Given the magnitude of GC-1-induced thermogenesis and the fact that thyroid 
hormone associated thermogenesis is generally attributed to BAT (42, 134) we 
felt that it was important to further explore whether BAT contributed to the 
thermogenic actions of GC-1. We used PET/CT imaging to examine the effects 
of GC-1 treatment on glucose metabolism in BAT and other peripheral tissues of 
mice placed under a mild cold stress (19-20°C). In untreated mice, 18F-FDG 
(FDG) uptake in interscapular BAT was readily apparent (Figure 3-13). Following 
GC-1 treatment, however, FDG uptake in interscapular BAT became 
indistinguishable from uptake in surrounding tissue, suggesting that GC-1 
strongly decreases the metabolic activity of interscapular BAT. Instead, GC-1 
treated mice exhibited diffuse FDG uptake into extra-abdominal regions 
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corresponding to scWAT. FDG uptake into equivalent regions of untreated mice 
was not detectable. Similar changes in glucose metabolism were observed 
during the hyperinsulinemic-euglycemic clamp study. Under hyperinsulinemic 
 
Figure 3-14. Glucose uptake in scWAT and BAT of control and treated ob/ob mice. 
14C-deoxyglucose uptake in scWAT and BAT of treated and untreated mice measured during a 
hyperinsulinemic-euglycemic clamp experiment (n = 6). Data are mean ± s.e.m. **P < 0.01, ***P 
< 0.001. 
conditions, 14C-deoxyglucose uptake into scWAT increased significantly in GC-1 
treated mice, while glucose uptake into BAT was decreased (Figure 3-14). To 
more firmly establish that BAT did not contribute to TR-mediated thermogenesis, 
 
Figure 3-15. Thermogenic gene expression in scWAT and BAT of sham and BAT-
denervated ob/ob mice. 
Thermogenic gene expression in BAT (A) and scWAT (B) of BAT-denervated and sham mice 
treated with or without GC-1 supplementation for 21 days (n = 6 per sham group; n = 3 per BAT 
denervated group). Data are mean ± s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001. 
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GC-1 was administered to mice in which intrascapular BAT activity had been 
ablated by surgical denervation (Figure 3-15A). While denervation reduced the 
expression of thermogenic markers in BAT, GC-1 treatment induced thermogenic 
gene expression in scWAT (Figure 3-15B) and resulted in weight (Figure 3-16A) 
and fat loss (Figure 3-16B) and elevation of body temperature (Figure 3-16C) 
that was indistinguishable between BAT-denervated mice and sham-treated 
controls, indicating that interscapular BAT does not make a measurable 
contribution to the metabolic effects elicited by GC-1.  
 
 
Figure 3-16. Indistinguishable weight and fat loss and elevated body temperature between 
BAT-denervated and sham treated mice. 
Weight loss (A), change in fat mass (B) and body temperature (C) were measured in BAT-
denervated and sham mice (n = 6 per sham group; n = 3 per BAT denervated group). Data are 
mean ± s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001. NS, not significant. 
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In Addition To GC-1, T3 Also Induces Adaptive Thermogenesis in scWAT of 
ob/ob Mice 
 
Figure 3-17. T3 treatment induces similar weight and fat loss and increases body 
temperature. 
Male ob/ob mice were administered GC-1, T3 or vehicle via daily intraperitoneal injections for 14 
days (n = 4). Body temperature (A), weight loss (B) and fat loss (C) of mice after 14 days of GC-
1, T3 or vehicle treatment. **P < 0.01, ***P < 0.001.  
 
To assess whether the phenomenon of WAT browning was unique to the agonist 
GC-1 or whether T3 could induce similar effects, we treated ob/ob mice with 
either GC-1 or pharmacological doses of T3. Both T3 and GC-1 induced 
thermogenesis, as indicated by increased the body temperature (Figure 3-17A), 
and elicited weight (Figure 3-17B) and fat loss (Figure 3-17C), although weight 
and fat loss were significantly greater with GC-1 than T3. Both compounds 
elicited similar patterns of gene expression in scWAT (Figure 3-18A), although 
for all genes profiled, the magnitude of induction was greater for GC-1 than T3.  
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Figure 3-18. Effects of T3 on the thermogenic genes and UCP1 protein expression in 
scWAT. 
Thermogenic gene (A) and UCP1 protein (B) expression in scWAT of GC-1, T3, or vehicle treated 
mice (n = 4). Data are mean ± s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001. 
 
Similarly, both ligands strongly increased UCP1 protein levels (Figure 3-18B), 
although again, the effect was greater with GC-1. Both compounds increased 
mitochondrial DNA (Figure 3-19A) and citrate synthase activity (Figure 3-19B) in 
scWAT. In contrast, genes involved in adaptive thermogenesis and UCP1 protein 
in BAT were almost universally unchanged or repressed by both T3 and GC-1 
(Figure 3-20, A and B). These data demonstrate that TR activation by the 
endogenous hormone T3 can elicit a program of adaptive thermogenesis within 
scWAT.  
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Figure 3-19. T3 increases mitochondria in scWAT. 
Mitochondrial DNA content and citrate synthase activity in scWAT of DIO mice treated with GC-1, 
T3 or vehicle (n = 4). Data are mean ± s.e.m. **P < 0.01, ***P < 0.001. 
 
 
 
Figure 3-20. Effects of T3 on the thermogenic genes and UCP1 protein expression in BAT. 
Thermogenic gene (A) and UCP1 protein (B) expression in BAT of GC-1, T3, or vehicle treated 
mice (n = 4). Data are mean ± s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001. 
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GC-1 Mediated Thermogenesis is Dependent Upon White Adipose Tissue 
 
 
Figure 3-21. Correlation between rate of fat loss and initial fat mass. 
Diet-induced obese (DIO) C57Bl/6 mice at 20-24 weeks of age were treated with GC-1. 
Correlation between adiposity (initial fat mass) and weight loss (Δ Fat) (n = 10). 
 
Since our data suggested that the thermogenic effects of TR activation were 
mediated by a program of adaptive thermogenesis in scWAT, we next asked 
whether WAT was necessary for the metabolic actions of GC-1. DIO mice of 
varying levels of adiposity were treated with GC-1 and weight loss was monitored 
as a surrogate indicator of metabolic increase. The rate of weight loss in these 
mice was found to correlate strongly with adipose mass (Figure 3-21). Next, we 
treated lean C57 mice, which had been raised on a chow diet and possessed 
very little scWAT, with GC-1. Lean mice exhibited no increase in metabolic rates 
(Figure 3-22, A-C) or elevated body temperature (Figure 3-22D). Contrastingly, 
obesity induced by high-fat feeding restored the ability of GC-1 to induce 
thermogenesis in C57 mice, as indicated by increased metabolic rate (Figure 3-
22, B and C) and elevated body temperature (Figure 3-22D). Collectively, these 
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results indicate that triglyceride-rich WAT is necessary for the thermogenic 
effects of GC-1 and are consistent with the hypothesis that thermogenic induction 
is mediated by scWAT.  
 
 
Figure 3-22. GC-1 increases metabolic rate and elevates body temperature in DIO but not 
lean mice. 
Lean and DIO mice at 16 weeks of age were fed, respectively, standard chow or high fat diet with 
or without GC-1 for 10 days (n = 4 per treatment). Metabolic rate, measured every 15, min in lean 
mice (A) and DIO mice (B). 72-h average of metabolic rate, day 7-9. (C) and body temperature 
(D) of lean and DIO C57Bl/6 mice with or without GC-1 treatment. Data are mean ± s.e.m. **P < 
0.01, ***P < 0.001. 
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WAT Browning by TR Agonists is at Least Partially Cell Autonomous 
It has been reported that T3 treatment of human white adipocytes elicits an 
increase in UCP1 expression and metabolic rate (45). In order to test whether the 
induction of adaptive thermogenesis may be direct action of TR agonists on 
adipocytes, we tested the ability of T3 and GC-1 to induce uncoupled respiration 
and genes involved in adaptive thermogenesis in human and mouse primary 
cells that had been differentiated into white adipocytes. In mouse adipocytes, 
GC-1 tended to induce genes involved in adaptive thermogenesis (Figure 3-23A) 
and uncoupled respiration more than doubled in GC-1-treated adipocytes (Figure 
3-23B). Together these results reveal that TR activation can induce uncoupled 
respiration in white adipocytes in a cell autonomous fashion that does not require 
central actions.  
 
 
Figure 3-23. GC-1 induces browning of white adipocytes in vitro. 
The TR agonist GC-1 elicit browning of white adipocytes. Thermogenic gene expression (A) and 
oxygen consumption rate (B) were measured in mouse stromal-vascular cells isolated from 
subcutaneous WAT that had been differentiated into adipocytes in the presence or absence of 
GC-1 (100 µM) (n = 4). Data are mean ± s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001. 
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DISCUSSION 
These data make it clear that TR activation can elicit profound changes in 
scWAT. Our observations are consistent with recent reports (135, 136) 
suggesting that various WAT depots possess differing abundances of beige 
adipocytes, which can be induced to perform UCP1-mediated thermogenesis, 
and classical white adipocytes, which cannot. Following GC-1 treatment of ob/ob 
mice, about 40% of subcutaneous white adipocytes exhibit a multilocular BAT-
like morphology, which is consistent with the suggestion by Wu et al. (136) that 
thermogenically competent beige cells, or precursors thereof (137), comprise 
about 40% of the adipocytes within scWAT. We found little evidence of GC-1 
giving rise to adipocytes within epididymal WAT that possessed brown-like 
morphology or function, consistent with the idea that adipocytes or adipocyte 
precursors within this depot have far less potential to conduct UCP1 mediated 
thermogenesis (136, 137). 
 
While we cannot rule out the possibility that tissues other than scWAT contribute 
to TR-stimulated thermogenesis, these data strongly suggest that scWAT 
contributes substantially to the observed thermogenic induction. To our 
knowledge, the only tissue that is known to be capable of mediating non-
shivering thermogenesis of the magnitude observed in the GC-1-treated ob/ob 
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mice is BAT, leading us to originally suspect that GC-1 must be restoring BAT 
function to these mice. However, several lines of evidence demonstrate that BAT 
is not involved in the thermogenesis observed in these mice. Gene expression 
data, tissue morphology, and functional studies using radiolabeled glucose to 
measure activity in vivo all reveal that BAT activity decreases in GC-1-treated 
mice. Furthermore, the denervation of interscapular BAT has absolutely no effect 
on thermogenic induction by GC-1. Collectively, these data indicate that a tissue 
other than BAT must be responsible for the thermogenic induction observed. It 
has recently been shown scWAT can at least partially compensate for the loss of 
BAT (138). While essentially all indications of BAT activity were decreased with 
TR agonist treatment, the same indicators were strongly increased in scWAT, 
which suggests that TR activation ameliorates the metabolic defects of ob/ob 
mice, not by restoring BAT activity, but instead by activating a compensatory 
program of adaptive thermogenesis in scWAT.  
 
Over the past year, numerous studies have demonstrated that a BAT-like 
program of thermogenesis can be induced within WAT depots, raising the 
potential of white fat to act as a thermogenic organ (73–76, 138). However, the 
metabolic and physiological changes that have accompanied most 
demonstrations of WAT browning have been modest, leading some to question 
the physiological relevance and pharmacological potential of this action (122). 
The magnitude of thermogenesis that accompanied GC-1 treatment and WAT 
68 
browning was striking. Initial dose-finding studies with GC-1 elicited a doubling of 
metabolic rate and chronic hyperthermia (>40°C) in ob/ob mice (data not shown). 
Could this level of thermogenesis truly be mediated by WAT? Nedergaard and 
Cannon have put forth a compelling argument that “The only physiologically 
relevant parameter [in regards to adaptive thermogenesis] is total UCP1 protein 
level per mouse” (122). Following GC-1 treatment, UCP1 transcript and protein 
levels in scWAT increase by orders of magnitude and approach those found in 
BAT. Furthermore, since obese mice possess such a large quantity of scWAT, 
not only do total UCP1 protein levels per mouse rise dramatically (Figure 3-24A), 
but scWAT becomes the predominant UCP1 containing tissue following GC-1 
treatment (Figure 3-24B). A similar calculation, based on transcript levels, 
 
Figure 3-24. UCP1 protein per mouse and per adipose tissue. 
(A) Relative total UCP1 protein levels per mouse in ob/ob mice fed 21 days with diets with or 
without GC-1 (n = 4–6). (B) Relative contribution of epiWAT, BAT and scWAT to total mouse 
UCP1 levels in ob/ob mice treated with GC-1. Data are mean ± s.e.m. ***P < 0.001. 
estimates that UCP1 levels in GC-1 treated ob/ob mice are about 5-fold higher 
than those found in BAT of C57 mice (Figure 3-25, A and B), approximating 
levels found following cold adaptation of these mice. Thus, if UCP1 protein levels 
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are the best indicator of a tissue’s thermogenic capacity, then WAT, and WAT 
alone, may indeed have capacity to mediate the observed thermogenesis.  
 
Figure 3-25. Ucp1 transcript and estimated total UCP1 in scWAT and BAT of ob/ob and DIO 
mice 
(A) Relative Ucp1 transcript levels in scWAT and BAT of ob/ob and DIO mice treated with GC-1 
(n = 4–6). (B) Total UCP1 protein levels per BAT and scWAT adipose depots estimated from 
relative Ucp1 transcript levels. Data are mean ± s.e.m. *P < 0.05, ***P < 0.001. 
 
Given the opposing functions of WAT and BAT, energy storage versus disposal, 
the conversion of white- to brown-like adipocytes could be expected to effectively 
reverse the function of WAT. Such changes are indeed observed with GC-1 
treatment. Normally, during weight loss, WAT would be expected to be releasing 
energy via lipolysis. However, GC-1 strongly increases the uptake of energy 
(glucose) into scWAT in the face of a significant energy deficit. Although not 
measured in this study, we presume that GC-1 also increases the uptake and 
metabolism of fatty acids in scWAT, as fatty acids seem to be the preferred 
substrate for UCP1-mediated thermogenesis (131). Consistent with this idea, 
there is a strong shift towards fatty acid oxidation that coincides with GC-1 
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treatment and thermogenic induction in WAT. The induction of thermogenesis in 
WAT coincides with striking improvements in insulin sensitivity and glucose 
control. Cold activation of BAT thermogenesis has been shown to strongly 
increase disposal of serum glucose and triglycerides (139, 140). In a similar 
fashion, our data suggest that WAT thermogenesis can also improve insulin 
sensitivity and glycemic control by increasing WAT mediated glucose disposal. 
Notably, the anti-diabetic effects of GC-1 appear to require thermogenic 
induction, as lower doses that do not induce thermogenesis impair rather than 
improve glycemic control (141). It is tempting to speculate that the striking 
decreases in serum triglyceride levels that we observed in a prior study when 
hyperlipidemic mice were treated with GC-1 could be mediated by adaptive 
thermogenesis driving uptake into WAT (142). These results, when analyzed 
alongside those of Bartelt et al. (139), suggest that UCP1-mediated 
thermogenesis, whether it be conducted by BAT or WAT, has remarkable ability 
to ameliorate metabolic disease and warrants further exploration. 
 
Mice treated with T3 or GC-1 become hyperthermic. The basis for the observed 
hyperthermia is not fully clear. These data, as well as a recent report (45), 
demonstrate that TR activation can induce UCP1 in white adipocytes in vivo and 
in vitro. However, increased UCP1 expression is not thought to be sufficient to 
elicit uncoupled respiration or thermogenesis, as UCP1 is not constitutively active 
and requires activation by fatty acids that are generated as part of a lipolytic 
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cascade following β-adrenergic stimulation (53). Thus, if we accept that the 
observed increase in heat production is UCP1 mediated, it follows that either 
SNS innervation of UCP1+ adipocytes must be increased or the requirement for 
SNS activation is decreased following TR agonism. It has been shown that TRs 
in the ventromedial hypothalamus are involved in the central regulation of 
metabolic rate (143). Although, in this study, increased metabolic rate was 
attributed to increased SNS innervation of BAT, it is easy to envision that central 
TR activation could increase SNS outflow to WAT in a similar 
fashion. Alternately, a recent report suggests that thermogenesis in beige 
adipocytes can be induced by an alternative pathway that does not require 
classical SNS activation via β-adrenergic signaling (144). The results here seem 
to be more consistent with the latter model, that the requirement for SNS 
stimulation is reduced following TR agonist treatment. That uncoupled respiration 
increases in cultured adipocytes indicates that, not only is UCP1 expression 
increased, but that UCP1 is also activated in the absence of any added β-
adrenergic agonists. ScWAT levels of norepinephrine do increase in ob/ob mice, 
but the increase is small and it is difficult to envision that this magnitude of 
change could mediate the dramatic effects seen in the scWAT of these mice. 
Also, a similar increase was not observed in DIO mice, despite clear evidence of 
scWAT browning in these mice.  
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While TR signaling is clearly implicated in thermogenesis, the browning of WAT 
has not yet been described as an effect of TR activation in vivo. TR-induced 
thermogenesis is nearly always attributed to BAT, although it is generally 
acknowledged that tissues other than BAT probably contribute to this action (126, 
145). However, our data indicate that functional BAT is not required for TR 
activation to elicit thermogenesis, since denervation of interscapular BAT, which 
accounts for the majority of BAT in mice, has no effect on GC-1-mediated 
thermogenesis in either ob/ob or DIO mice. Conversely, scWAT appears to be 
required for the thermogenic effects of GC-1 as all thermogenic induction is lost 
when GC-1 is administered to lean mice that possess little scWAT. Although lean 
mice do possess white adipocytes, the lack of triglyceride stores within these 
cells presumably limit their ability to generate intracellular free fatty acids 
necessary to activate UCP1. Pharmacological doses of T3 were also able to 
induce a program of adaptive thermogenesis in scWAT, demonstrating that the 
browning of WAT is not unique to GC-1 and may, instead, represent a common 
effect of TR activation in scWAT. Could UCP1 mediated thermogenesis in WAT 
represent an unappreciated component of 'thyroid thermogenesis'? If WAT 
mediated thermogenesis were to contribute significantly to systemic 
thermogenesis elicited by TRs, then the loss of this effect would be expected to 
result in hypothermia or require a compensatory increase in alternative 
mechanisms of thermogenesis, such as classical BAT mediated thermogenesis. 
Indeed, both are common effects of impaired TR signaling and could explain why 
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the loss of TR signaling due to thyroid ablation, loss of TRs, or loss of DIO2 
results in hypothermia and thermogenic defects despite indications of increased 
BAT recruitment, such as increased UCP1 protein (10, 16). This model could 
also resolve the paradoxical decrease in BAT activity that has been observed by 
us and others (146, 147), that occurs concomitant with hyperthermia, when 
rodents are given supraphysiological doses of T3 or T4. Thus, we speculate that 
WAT-mediated thermogenesis may represent a physiologically relevant effect of 
TR activation that requires functional TR signaling. 
 
In conclusion, TR activation by T3 and the synthetic agonist GC-1 induces a 
genetic program of BAT-like thermogenesis and uncoupled respiration in scWAT. 
TR agonism elicits a functional conversion of WAT into a brown adipose-like 
tissue that coincides with striking anti-obesity and anti-diabetic actions that we 
suggest demonstrates the profound pharmacological potential of WAT browning. 
As GC-1 has been previously shown to evoke rapid weight loss in non-human 
primates (32), we believe that there is strong potential that these results could be 
translated to man. 
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Materials and Methods 
Animals 
Male C57Bl/6 and ob/ob mice were obtained from Harlan Laboratories. Mice 
were housed in a temperature-controlled environment with 12 h light/dark cycles 
and fed standard irradiated rodent chow ad libitum. At six weeks of age, C57Bl/6 
mice were fed a high-fat diet (HFD) containing 0.2% cholesterol (D12079B, 
Research Diets) for 8 weeks to induce obesity, unless otherwise noted. TR 
agonists T3 and GC-1 were administered to 12 week-old ob/ob mice via 
intraperitoneal injections (0.3 mg/kg/d GC-1, 0.06 mg/kg/d T3) or admixed in 
chow (3 mg/kg-diet). Lean and DIO C57B1/6 mice 14-16 weeks of age were 
administered T3 or GC-1 via intraperitoneal injections (0.45 mg/kg/d GC-1, 0.3 
mg/kg/d T3) or admixed into chow (3 mg/kg-diet) or HFD (4.8 mg/kg-diet), 
respectively. Control groups received appropriate vehicle solutions or diets 
identical to treatment groups. All animal experiments were approved by the 
Institutional Animal Care and Use Committee of Houston Methodist Research 
Institute.  
 
BAT Denervation 
BAT denervation surgery was performed on ob/ob and C57Bl/6 mice at 3 to 4 
weeks of age. Mice were anesthetized with isoflurane and body temperature was 
maintained with a warming pad. Interscapular BAT lobes were elevated from the 
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underlying cervical and scapular caudally to separate it from the surrounding 
muscle and expose sympathetic nerves. The five intercostal nerves of each lobe 
were isolated and a section of each nerve was removed without damaging the 
vasculature. The sham procedure was identical except nerves were not 
transected.  
 
Hyperinsulinemic-Euglycemic Clamp 
Hyperinsulinemic-euglycemia clamps were performed at the Mouse Metabolism 
Core at Baylor College of Medicine. Prior to the clamp, a catheter was inserted 
into the right internal jugular vein. After recovery, mice were administered GC-1 
admixed in diet or control diet for 10-12 days. On the day of the experiment, 
conscious, overnight-fasted mice received a primed intravenous infusion of 3H-
glucose (10 µCi) to measure glucose turnover. The hyperinsulinemic-euglycemic 
clamp was performed with continuous infusion of insulin (12 mU/kg/min) and 
variable infusion of glucose to maintain euglycemia. Blood samples were 
collected every 10 min to measure glucose concentrations. Tissue-specific 
uptake was performed using 14C-deoxyglucose (10 µCi) 45 min before the end of 
the clamp experiment. 
 
PET/CT Imaging 
18F-deoxyglucose (18F-FDG) (200 µCi) was administered to mice which had 
received GC-1 via intraperitoneal injection for 14 days. Animals were imaged 1 h 
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after the injection at the TMHRI preclinical imaging core. microPET/CT imaging 
was performed using Siemens Inveon dedicated PET and Siemens Inveon 
multimodality system in docked mode. Anesthetized animals were first subjected 
to a whole-body CT scan and then to a static 18F PET scan. CT and PET images 
were aligned and reconstructed with Inveon Research Workplace software 
(Siemens).  
 
Primary Cell Culture 
Mouse subcutaneous preadipocytes were collected from inguinal fat depots of 4-
week old C57Bl6 mice as described previously (148). Briefly, tissues were 
digested in PBS containing collagenase I (1.5 mg/ml) and dispase (2.5 mg/ul) at 
37°C for 45 min. Undigested tissue and epithelial cells were removed with 100-
µm and 40-µm cell strainers, respectively. The stromal vascular cells were 
cultured in DMEM/F-12 (Invitrogen) containing 10% FBS (Sigma). For adipocyte 
differentiation, confluent cells were induced in DMEM/F12 containing 10% FBS, 
isobutulmethylxanthine (IBMX) (0.5 mM), dexamethasone (1 µM), insulin (5 
µm/ml), and rosiglitazone (100 nM). After 2 days, cell received fresh media 
containing 10% FBS and insulin, and the media was changed subsequently 
every 2 days for 8–9 days. For TR agonist treatment, cells were treated with 100 
µM of GC-1 or vehicle during differentiation.  
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Oxygen Consumption Rate Analysis 
Oxygen consumption rates were determined in mouse adipose tissue and 
subcutaneous adipocytes using a modified protocol (149). Inguinal fat depots 
were extracted from mice and rinsed in XF-DMEM (Seahorse Bioscience) 
containing 2.5 mM glucose and 1 mM sodium pyruvate. Adipose tissues were cut 
into small pieces (~10 mg) and rinsed in XF-DMEM media, and immobilized in 
XF24-well Islet Flux plate (Seahorse Bioscience). Oxygen consumption rate was 
measured using an Extracellular Flux XF24 analyzer (Seahorse Bioscience) at 
37°C. The XF24 Analyzer mixed the media in each well for 2 min before 
measurements to allow oxygen partial pressure to equilibrate. Basal OCR was 
measured simultaneously in all wells four times. Tissue replicates from different 
mice were analyzed in independent experiments and results were normalized to 
tissue weight. Despite repeated efforts, we were unable to measure uncoupled 
respiration, presumably due to poor penetrance of oligomycin into the tissue.  
 
For subcutaneous white adipocytes, preadipocytes were plated in a 24-well XF24 
cell culture microplates followed by adipocyte differentiation. On the day of the 
experiment the cells were washed with XF-DMEM and 500 µl of XF-DMEM was 
added to each well, and the cells were incubated at 37°C without CO2 for 1 h 
before the assay. Uncoupled respiration was measured after the addition of 
oligomycin (2 µg/ml), an ATP synthase inhibitor.  
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Metabolic Phenotyping 
Glucose tolerance tests were performed on mice fasted for 6 h and administered 
a bolus of glucose (2 g/kg BW) via oral gavage. Blood glucose concentrations 
were measured at indicated intervals with a standard glucometer (OneTouch). 
Body composition analysis was performed using noninvasive quantitative NMR 
(EchoMRI). 
 
Indirect Calorimetry 
Metabolic rate, RER, food intake, and ambulatory activity were evaluated by 
using a Comprehensive Laboratory Animal Monitoring System (Columbus 
Instruments). Mice were individually housed in metabolic cages with food and 
water ad libitum and allowed to acclimate for 48 h prior to experimentation. Mice 
were fed chow with or without GC-1 admixed. CO2 and O2 levels were measured 
at 15 min intervals. Metabolic rate, food intake, and ambulatory activity were 
averaged over 72-h. 
 
Acute Cold Challenge 
Mice were individually housed with food and water ad libitum and challenged with 
acute cold at 4°C. Core body temperature was measured prior to cold exposure 
and at time intervals indicated using a digital thermometer with RET-3 rectal 
probe for mice. 
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RNA Extraction and Real-time qPCR 
Total RNA was extracted and isolated using QIAzol and RNeasy Mini Kit 
(Qiagen). First strand cDNA was transcribed from total RNA using SuperScript 
VILO master mix (Invitrogen). TaqMan real-time PCR reactions were performed 
on a LightCycler 480 Real-Time PCR system (Roche), and relative mRNA levels 
were calculated by the comparative Ct method using β-actin as internal control. 
TaqMan primer/probe sets were supplied by Applied Biosystems. Assay IDs are 
available upon request. 
 
Mitochondrial DNA Content 
RNA-free genomic DNA was isolated from epididymal WAT, subcutaneous WAT 
and BAT using DNeasy Blood and Tissue Kit (Qiagen). Real-time quantitative 
qPCR analysis was used to measure the genomic level of mitochondrial NADH 
dehydrogenase subunit 1 (ND1), which was normalized to nuclear 18S ribosomal 
DNA. 
 
Histology 
Adipose tissues were fixed in 10% buffered formalin, embedded in paraffin, and 
sectioned at 4 µm. Sections were stained with hematoxylin and eosin. 
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Adipose Tissue Citrate Synthase Activity 
BAT, inguinal WAT, and epididymal WAT were homogenized in CelLytic MT lysis 
reagent (Sigma) containing a cocktail of protease inhibitors (Roche). Lysates 
were centrifuged to remove cell debris and lipids. Protein concentration was 
determined using a NanoDrop spectrophotometer (Thermo Fisher Scientific Inc.). 
Citrate synthase activity in the protein lysates was measured with a kit (Sigma) 
following the manufacturer’s protocol. 
 
Catecholamines 
Norepinephrine content in BAT and inguinal WAT were determined using a 
commercially available ELISA kit and according to manufacturer’s instructions 
(Rocky Mountain Diagnostics). Tissues were homogenized in buffer containing 1 
mM EDTA and 4 mM Na2S2O5 to stabilize and prevent degradation of 
norepinephrine. 
 
Immunoblotting 
Adipose tissue was homogenized in tissue extraction reagent (Invitrogen) 
containing a cocktail of protease inhibitors (Roche). Equivalent amounts of total 
protein were separated by SDS-PAGE, transferred to polyvinylidene difluoride 
membranes and probed with antibodies against UCP1 (662045) (Millipore) and 
α-tubulin (ab7291) (abcam), and with conjugated-HRP anti-rabbit (sc-2004) and 
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anti-mouse antibodies (sc-2005) (Santa Cruz Biotechnology). Blots were 
visualized by autoradiography using Amersham ECL Western Blotting Detection 
Regents (GE Healthcare). 
 
UCP1 Quantification 
Relative UCP1 concentrations were calculated by using ImageJ to quantify UCP1 
from immunoblots and normalizing to α-tubulin. Total UCP1 protein and Ucp1 
transcripts per tissue were calculated based on the fat mass values obtained by 
quantitative NMR and multiplied by the relative UCP1 protein or transcript 
concentration, approximating the fat composition in mice to be 27.8% epididymal 
WAT, 70% subcutaneous WAT, and 1% (150, 151). Total UCP1 levels per 
mouse were determined by the sum of UCP1 in epiWAT, scWAT, and BAT. 
 
Statistical Analysis 
Data are presented as mean ± s.e.m. A p-value of less than 0.05 was considered 
significant. Student’s t-test was used for pairwise comparisons. Correlation 
evaluated by Pearson’s correlation coefficient. 
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CHAPTER 4 CONCLUDING REMARKS AND FUTURE 
PRESPECTIVES 
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Thyroid hormones and their receptors were discovered many years ago and their 
functions have been studied extensively. It has long been known that thyroid 
hormones regulate many aspects of lipid metabolism and modulation of TRs has 
been of therapeutic interest to combat obesity and its metabolic complications. 
TR activation has many effects on lipid metabolism in numerous tissues and 
work in this thesis was aimed at providing further insights into the effects of TR 
activation in liver and adipose tissue. We report two novel mechanisms by which 
TR regulates lipid metabolism: i) thyromimetics lower cholesterol independent of 
LDLR by increasing bile acid excretion via hepatic Cyp7a1 induction and ii) TR 
activation by GC-1 induces a functional conversion of white to brown fat. 
Importantly, both have potential translational implications to treat metabolic 
diseases such as hyperlipidemia, diabetes, and obesity. 
 
What is the contribution of Cyp7a1 to TR-mediated cholesterol lowering? 
 
The primary mechanism of nearly all cholesterol lowering therapeutics is 
increasing hepatic cholesterol uptake through the LDLR. This is the mechanism 
of action of the most commonly prescribed cholesterol drugs, the statins, as well 
as a new class of cholesterol lowering drugs, PCSK9 inhibitors. Thyroid 
hormones were also thought to lower cholesterol through stimulating expression 
of LDLR, however, our data show that TR agonists lower cholesterol via a 
mechanism that is independent of the LDLR. Thyromimetics lower cholesterol in 
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LDLR null mice by induction of hepatic Cyp7a1, thus converting cholesterol to 
bile acids for excretion via reverse cholesterol transport. Our data suggest 
Cyp7a1 induction may be the primary mechanism of TR-mediated cholesterol 
reduction. Further studies in Cyp7a1 null mice are warranted to quantitatively 
address the contribution of Cyp7a1 to the cholesterol reducing actions of TR 
agonists. This mechanistic distinction is important as Cyp7a overexpression 
lowers serum cholesterol in rats and rabbits lacking LDLR, which suggests that 
thyromimetics could be used to treat patients with homozygous familial 
hypercholesterolemia, who functional LDLR. 
 
What is the physiological relevance of WAT browning? 
 
 
BAT is generally presumed to be the mechanism by which thyroid hormone 
induces adaptive thermogenesis; however, the relationship between TR action 
and BAT activity is complex and contradictory evidence exists. For example, 
impaired TR signaling results in hypothermia and thermogenic defects despite 
evidence of increased BAT recruitment and UCP1 protein (10, 16). Similarly, we 
show that the TR agonist GC-1, which induces thermogenesis, significantly 
represses BAT activity. Further, we show that TR thermogenesis does not 
require functional BAT by demonstrating that denervation of interscapular BAT 
has no effect on GC-1-mediated thermogenesis. Thus we suggest that TR-
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mediated thermogenesis can be mediated exclusively by the browning of WAT. 
This model can potentially resolve some of the confusion regarding the 
relationship between TR action, BAT, and adaptive thermogenesis, such as the 
paradoxical decrease in BAT activity that has been previously reported to 
coincide with thyroid hormone-induced hyperthermia (146, 147)  
 
While it is generally assumed tissues other than BAT probably contribute to 
thyroid thermogenesis (126, 145), the discovery of alternative mechanisms of 
thermogenesis have proven elusive. Our data demonstrate that TR activation by 
GC-1 can functionally convert white to brown fat and induce adaptive 
thermogenesis in WAT. The contribution of WAT browning to TR thermogenesis 
should be further studied in knockout mice lacking UCP1 and TRs in WAT and 
BAT. The browning of white fat is an unrecognized function of TR activation in 
WAT and may represent a missing component of thyroid thermogenesis. 
 
Does TR-mediated thermogenesis and the browning of WAT require SNS 
innervation? 
 
The SNS is a major regulator of thermogenesis, as β adrenergic signaling is 
required to activate a cAMP/PKA/cAMP response element-binding protein 
signaling cascade, which controls transcription of the thermogenic program. It is 
well accepted that agonism of β adrenergic receptors that results from cold 
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exposure activates the thermogenic program in brown and beige fat. Similarly, 
thyroid hormones have been shown to affect thermogenesis via SNS activation 
(143). However unlike most other examples of beige fat activation, GC-1-induced 
browning of WAT does not seem to require β-adrenergic stimulation. Two key 
results strongly suggest that WAT browning by GC-1 is cell autonomous and 
does not require SNS stimulation: i) the in vitro beiging of white preadipocytes in 
the absence of catecholamine stimulation and ii) the in vivo browning of WAT 
without a large concomitant increase in WAT norepinephrine levels. A recent 
study in mice that lack all three β-adrenergic receptors (beta-less mice) supports 
the contention that the browning of white adipocytes is a cell-autonomous action 
that does not require SNS stimulation (144). Whether the SNS is required for TR-
mediated WAT browning should be further investigated in beta-less mice. 
Importantly, since the biggest challenge of adaptive thermogenesis for anti-
obesity therapy has been the induction of thermogenic genes is generally 
insufficient to induce adaptive thermogenesis and β-adrenergic stimulation has 
always been thought to be additionally required. Thus, a challenge facing the 
utilization of adaptive thermogenesis as an anti-obesity therapy has been the 
question of how to simultaneous induce the thermogenic program and also 
activate it. However, our data indicates that the TR agonist GC-1 both induces 
and activates adaptive thermogenesis, which suggests that TR agonist-mediated 
WAT browning could represent an effective strategy to combat metabolic 
disease.  
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